# First Regular Session Seventy-second General Assembly STATE OF COLORADO

REVISED

LLS NO. R19-0909.01 Rebecca Hausmann x2172

**SJR19-007** 

### SENATE SPONSORSHIP

**Moreno,** Bridges, Fenberg, Fields, Gardner, Hill, Lundeen, Scott, Tate, Todd, Williams A., Winter, Woodward, Cooke, Coram, Court, Crowder, Danielson, Donovan, Foote, Garcia, Ginal, Gonzales, Hisey, Holbert, Lee, Marble, Pettersen, Priola, Rankin, Rodriguez, Smallwood, Sonnenberg, Story, Zenzinger

### HOUSE SPONSORSHIP

**Kraft-Tharp,** Buentello, Caraveo, Gray, Hooton, Landgraf, Lontine, McKean, Melton, Michaelson Jenet, Roberts, Titone, Valdez A., Valdez D., Arndt, Baisley, Becker, Beckman, Benavidez, Bird, Bockenfeld, Buck, Buckner, Carver, Catlin, Coleman, Cutter, Duran, Esgar, Exum, Froelich, Galindo, Garnett, Geitner, Hansen, Herod, Humphrey, Jackson, Jaquez Lewis, Kennedy, Kipp, Larson, Lewis, Liston, McCluskie, McLachlan, Mullica, Neville, Pelton, Ransom, Rich, Saine, Sandridge, Singer, Sirota, Snyder, Soper, Sullivan, Tipper, Van Winkle, Weissman, Will, Williams D., Wilson

**Senate Committees** 

### **House Committees**

## **SENATE JOINT RESOLUTION 19-007** 101 CONCERNING DESIGNATION OF THE FIRST FULL WEEK OF MAY AS 102 "TARDIVE DYSKINESIA AWARENESS WEEK". 1 WHEREAS, Many people with serious, chronic mental illness, 2 such as schizophrenia and other schizoaffective disorders, bipolar 3 disorder, or severe depression, require treatment with medications that 4 work as dopamine receptor blocking agents (DRBAs), including 5 antipsychotics; and 6 WHEREAS, While ongoing treatment with these medications can 7 be very helpful, and even lifesaving, for many people it can also lead to 8 Tardive Dyskinesia (TD); and 9 WHEREAS, Many people who have gastrointestinal disorders, 10 including gastroparesis, nausea, and vomiting, also require treatment with

Final Reading April 10, 2019

SENATE Final Reading April 9, 2019

1	DRBAs; and
2 3	WHEREAS, Treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to TD; and
4 5 6	WHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities; and
7 8 9 10	WHEREAS, In some cases, people with TD experience involuntary and uncontrolled movement of the arms, legs, fingers, toes, tongue, lips, or jaw; swaying movements of the trunk or hips; or impacts to the muscles associated with walking, speech, eating, and breathing; and
11 12 13	WHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after the person has discontinued use of such medications; and
14 15	WHEREAS, Not everyone who takes a DRBA develops TD, but if TD develops it is often permanent; and
16 17 18	WHEREAS, Common risk factors for TD include advanced age, alcoholism, substance abuse disorders, being postmenopausal, and mood disorders; and
19 20 21	WHEREAS, A person is at higher risk for TD after taking DRBAs for three months or longer, and the longer a person takes DRBAs, the higher the risk of developing TD; and
22 23 24	WHEREAS, Studies suggest that the overall risk of developing TD following prolonged exposure to DRBAs is between 10 and 30 percent; and
25 26	WHEREAS, It is estimated that approximately 500,000 individuals in the United States suffer from TD; and
27 28 29	WHEREAS, Years of challenging research have resulted in scientific advancements since 2017, with two new treatments for TD approved by the United States Food and Drug Administration; and
30 31	WHEREAS, TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed; and

-2-

1	WHEREAS, Patients taking DRBAs should see their health care
2	providers for regular evaluations to ensure that any signs of TD are
3	recognized; and
4	WHEREAS, Patients with TD often suffer embarrassment due to
5	abnormal and involuntary movements, which leads them to withdraw
6	from society and isolate themselves as the disease progresses; and
7	WHEREAS, The caregivers of patients with TD face many
8	challenges and are often responsible for the overall care of the TD
9	patient; now, therefore,
10	Be It Resolved by the Senate of the Seventy-second General
11	Assembly of the State of Colorado, the House of Representatives
12	concurring herein:
13	That the first full week of May is proclaimed "Tardive Dyskinesia
14	Awareness Week", with the goals of:
15	(1) Raising awareness of this potentially debilitating disease;
16	(2) Encouraging individuals not afflicted with TD to consider the
17	effects of TD on individuals and society; and
18	(3) Encouraging Coloradans to contribute to charities supporting
19	TD research and awareness.
20	Be It Further Resolved, That copies of this Joint Resolution be sent
21	to the Colorado chapter of the National Alliance on Mental Illness,
22	Mental Health Colorado, the Colorado Governor's office, the Department
23	of Health Care Policy and Financing, the Department of Public Health
24	and Environment, the Office of Saving People Money on Health Care,
25	and the office of the Ombudsman for Behavioral Health Access to Care.

-3-